ArticleInternational journal of general medicine2026
The New Era of Precision Oncology. Practicing Pathology in Low Resource Countries and Settings.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized or precision medicine is the future of cancer treatment modalities. It is advancing at a rapid pace and transforming the practice of oncology. Personalized oncology demands personalized (precision) pathology. New biomarkers are continuously being discovered, and there is increasing emphasis on individualized care. The primary aim of oncology in the new era is to utilize the molecular characteristics of malignant tumors to design the best and most optimal treatment for each cancer patient. Molecular diagnostics is the cornerstone of precision oncology. Pathology always had a crucial and major role in cancer care encompassing all aspects of oncology and this role is becoming even more critical. It is expanding and transforming into an even more dynamic specialty. Pathologists in developing countries and low resource settings need to understand these changes, take up the new challenges and opportunities, and modify their practice accordingly not only in order to remain relevant, but even more importantly to embrace a more central and vital role in cancer care. They need to embrace molecular technologies like next-generation sequencing (NGS) and familiarize themselves with new and emerging molecular biomarkers, and how these help in deciding the best targeted therapy for individual cancer patients. They also need to incorporate digital pathology (DP) and artificial intelligence (AI) in their routine practice. Herein, we present our views and perspective regarding opportunities and challenges for pathologists in the era of "precision oncology".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.